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Intestinal gluconeogenesis is involved in the control
of food intake. We show that mu-opioid receptors
(MORs) present in nerves in the portal vein walls
respond to peptides to regulate a gut-brain neural
circuit that controls intestinal gluconeogenesis and
satiety. In vitro, peptides and protein digests behave
as MOR antagonists in competition experiments.
In vivo, they stimulate MOR-dependent induction
of intestinal gluconeogenesis via activation of
brain areas receiving inputs from gastrointestinal
ascending nerves. MOR-knockout mice do not carry
out intestinal gluconeogenesis in response to
peptides and are insensitive to the satiety effect
induced by protein-enriched diets. Portal infusions
of MOR modulators have no effect on food intake in
mice deficient for intestinal gluconeogenesis. Thus,
the regulation of portal MORs by peptides triggering
signals to and from the brain to induce intestinal
gluconeogenesis are links in the satiety phenomenon
associated with alimentary protein assimilation.
INTRODUCTION
Given the worldwide increase in cases of obesity and associated
illnesses such as type 2 diabetes, the scientific community has
been urged to improve our understanding of the mechanisms
underlying energy homeostasis. An increasingly important area
of investigation involves the hormonal signals that the gut
produces in response to nutrient assimilation and that modulate
hunger, such as cholecystokinin (CCK), glucagon-like peptide 1,
and peptide YY (Gibbs et al., 1976; Morley et al., 1983; Turton
et al., 1996). In particular, the enteric neural system plays a key
role in sensing and transmitting signals to the brain (Berthoud,
2004; Moran, 2000; Vahl et al., 2007).Intestinal gluconeogenesis is a newly described process
(Croset et al., 2001; Mithieux et al., 2004a; Mithieux et al.,
2004b; Rajas et al., 1999; Rajas et al., 2000) that influences the
control of glucose and energy homeostasis in the fed postab-
sorptive state (for review see Mithieux, 2009). The induction of
intestinal gluconeogenesis translates into a release of glucose
in the portal vein, which collects blood from the whole gut. Its
detection by a portal glucose sensor and the transmission of
this signal to the brain by the peripheral neural system initiate
a decrease in hunger and an improvement in the insulin sensi-
tivity of hepatic glucose production. This above all takes
place in two particular nutritional situations, i.e., feeding with
a protein-enriched diet (PED) (Mithieux et al., 2005; Pillot et al.,
2009) and after gastric bypass surgery (Troy et al., 2008). The
role played by intestinal gluconeogenesis in the satiety initiated
by PED has been confirmed recently. Indeed, mice with an
intestinal-specific knockout of the catalytic subunit (G6PC) of
glucose-6 phosphatase (G6Pase, the essential enzyme of gluco-
neogenesis) proved insensitive to PED-induced satiety (Penhoat
et al., 2011).
A long-known and intriguing property of proteins is that
a number of them, especially those involved in human nutrition
such as caseins from milk, release oligopeptides exhibiting
m-opioid activity in vitro upon partial proteolytic digestion (Ziou-
drou et al., 1979). Moreover, the literature on the subject
mentions the m-opioid activity of various oligopeptides, of which
the minimal structure required is a dipeptide (Capasso et al.,
1997; Moritoki et al., 1984; Schiller et al., 2002; Shiomi et al.,
1981). It is also known that the modulation of m-opioid receptors
(MORs) can interfere with the control of food intake. Agonists
enhance food intake, whereas antagonists inhibit it (see the
review by Yeomans and Gray, 2002). Interestingly, MORs are
most widely expressed in two organs of the body: the brain,
especially in the regions implicated in the control of food intake
and reward-driven appetite (Ding et al., 1996; George et al.,
1994;Will et al., 2003), and the small intestine, where they control
gut motility, including bowel movements (Hedner and Cassuto,
1987; Sternini, 2001; Sternini et al., 2004). Food proteins areCell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc. 377
absorbed from the intestinal lumen after incomplete proteolysis.
It has been hypothesized that food proteins (e.g., caseins) might
exert a systemic signaling role via their proteolytic digests with
m-opioid activity (Meisel and FitzGerald, 2000; Zioudrou et al.,
1979). However, that the latter might reach the brain following
oral ingestion seems questionable. Indeed, b-casomorphin 1-7
(b1-7), an MOR agonist released by the digestion of b-casein,
is degraded by the liver (Kreil et al., 1983) and is not detected
in systemic blood after the ingestion of milk or dairy products
(Teschemacher et al., 1986). Alternatively, MOR modulators
from an alimentary origin might act at a gastrointestinal or
mesenteric portal site (Holzer, 2009; Meisel and FitzGerald,
2000). In line with this rationale, naloxone (Nalox), a chemical
MOR antagonist that is actively degraded by the liver (Green-
wood-Van Meerveld et al., 2004; Reimer et al., 2009), can
suppress food intake when given orally in humans (Yeomans
and Gray, 2002). This suggests that the drug might modulate
hunger sensations from a gastrointestinal site.
In this work, we first use intraportal infusions of MOR agonists
and antagonists to establish that MORs present at a portal site
initiate a gut-brain neural circuit of intestinal gluconeogenesis
regulation. Then, we demonstrate that alimentary proteins act
at this gastrointestinal site to induce gut gluconeogenesis-
dependent satiety via the MOR antagonist properties of their
oligopeptide digests.
RESULTS
Portal MORs Regulate Intestinal Gluconeogenesis
via a Gut-Brain Neural Circuit
To elucidate the role of the portal neural system in the induction
of intestinal gluconeogenesis gene expression by food protein,
we initially studied the effect of a PED in rats after periportal
treatment by capsaicin, a drug that inactivates afferent nerves.
Interestingly, there was no induction of either G6Pase activity
or PEPCK-C (phosphoenolpyruvate carboxykinase-cytoplasmic
form) protein expression in capsaicin-treated rats fed on a PED,
unlike what occurred in sham-operated rats in which strong
induction was observed (Figures S1A and S1B, available online).
We studied the abundance of neuronal fibers, visualized via the
presence of the neuronal marker PGP9.5, around the portal vein
walls after capsaicin treatment. In agreement with the observa-
tion that portal nerves are mainly composed of afferents
(Berthoud, 2004), the number of neuronal fibers was dramatically
reduced after administration of the drug (Figure S1C). This
confirmed the suppression of the afferents by the drug. Then,
to test the putative role of MORs in this induction, we infused
MOR-regulators in conscious rats with a catheter implanted in
a mesenteric vein, as described previously (Mithieux et al.,
2005). Three infusion rates were studied. The intermediate rate
approximately matched (on a 1:1 molar basis) the appearance
of b1-7 from a protein-enriched meal representative of the PED
used above. It is noteworthy that both b1-7 and a selective
MOR agonist D-Ala2, N3-Me-Phe4, Gly5-ol (DAMGO) signifi-
cantly suppressed intestinal G6Pase activity after an 8 hr infusion
(Figure 1A). On the contrary, both Casoxin C (CasoC), an MOR
antagonist stemming from kappa-casein (Chiba et al., 1989)
and Nalox markedly enhanced G6Pase activity (Figure 1A).378 Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc.Comparable results were obtained for the expression of the
PEPCK-C protein (Figure 1B). When a metabolic glucose tracer
(tritiated on carbon 3) was associated with the Nalox infusion
at the end of the experiment, there was a decrease in 3[3H]
glucose-specific activity in the portal vein compared to that in
artery (Figure 1C). This revealed that newly synthesized unla-
beled glucose had been released in the blood by the intestine.
Intestinal glucose production (IGP) represented 25%–30% of
total endogenous glucose production (EGP) after the infusion
of Nalox (Figure 1C). IGP was sufficient to counterbalance intes-
tinal glucose uptake (IGU), so no lowering of plasma glucosewas
observed in the portal vein (Figure 1C). We previously showed
that this is sufficient to initiate portal glucose sensing and
suppression of food intake (Mithieux et al., 2005; Troy et al.,
2008). On the contrary, no such appearance of unlabeled
glucose was observed in rats infused with DAMGO (Figure 1C).
In this case, there was no decrease in the 3[3H]glucose-specific
activity and the level of plasma glucose was lower in the
portal vein compared to that in the artery (Figure 1C), reflecting
glucose utilization by the gut. It must be noted that we did not
determine IGP after infusion of saline. Because of the low accu-
racy of the tracer dilution method (this is a weakness of this
approach), the flux of glucose released by the intestine under
basal condition is hardly distinguishable from nil (see e.g.,
Mithieux et al., 2005; Pillot et al., 2009 for discussion of this
point). In agreement with what could be expected from the effect
of MOR effectors on intestinal gluconeogenesis, rats infused
with MOR antagonist (CasoC) in the portal vein exhibited
decreased food intake, whereas those infused withMOR agonist
(b1-7) exhibited increased food intake (Figure S1D).
We used three approaches to further determine the role played
by portal MORs. Immunohistochemical studies using the
neuronal marker PGP9.5 (Figure 2A, in red) revealed the pres-
ence of neuronal fibers in the walls of the portal vein both in
rats (Figure 2A) and inmice (not shown). In addition, the presence
of MOR-1 (green fluorescence) was also detected in close
vicinity to the portal vein (Figure 2A). Merging both fluorescence
channels (Figure 2A, in yellow) revealed close colocalization of
both proteins in certain neuronal structures. Interestingly, we
observed comparable colocalization of MOR-1 and PGP9.5 in
the portal branches irrigating the portal spaces of the human liver
(Figure 2A). Furthermore, the presence of MOR-1 within the
portal vein walls was confirmed by western blot (Figure 2B). In
contrast, MOR-1 was not detected in the ileum of MOR-KO
mice,which confirmed the specificity of the detection (Figure 2B).
Then, we studied the effect of b1-7 and CasoC separately on
intestinal gluconeogenesis gene expression in capsaicin-treated
rats. There was no effect of either effector on gluconeogenic
enzymes in rats with portal denervation (Figure S1E), strongly
suggesting that the periportal neural system is crucial for the
transmission of the MOR-signal. Lastly, we evaluated the impact
of b1-7 and Nalox on the regions of the brain implicated in the
reception of the signals from the portal area. This is linked to
the dorsal vagal complex (DVC), which is the main receiver of
inputs from the vagus nerve, and to the parabrachial nucleus
(PBN), which mainly receives afferents from the spinal cord (for
a review see Berthoud, 2004). Using immunohistochemistry,
we studied the expression of the immediate-early gene protein
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Figure 1. Effect of Portal Infusion of MOR Effectors on Gut Gluconeogenesis in Rats
(A and B) The rats (fed on an SED) were infused via the portal vein with saline or MOR effectors at the indicated rates, for 8 hr. (A) G6Pase activity. (B) PEPCK-C
protein amount estimated by western blot. The data are expressed as the means ± SEM of six to eight rats per group. *, different from saline infusion, p < 0.05
(Tukey’s post hoc test).
(C) EGP and intestinal glucose fluxes were determined after portal infusions of metabolites (8.33 106mmol/kg/min). The results are themeans ±SEM of five rats
per group. aDifferent from value in artery, p < 0.05, Student’s two tailed test for paired values. bDifferent from DAMGO, p < 0.05, one-way ANOVA followed by
Tukey’s post hoc test.
See also Figure S1.product C-FOS, a well-recognized marker of neuronal activation
(Bullitt, 1990; Sagar et al., 1988). The portal infusion of b1-7 did
not elicit significant C-FOS activation in any of these regions,
compared to saline infusion (Figures 3 and S2). On the contrary,
Nalox infusion caused a 2- to -3-fold induction of C-FOS in the
DVC, i.e., the area postrema (AP) and the nucleus of the tractus
solitaris (NTS), and in the PBN (Figures 3 and S2). Interestingly,
no activation took place in any of these nuclei in rats whose
portal vein had been treated by capsaicin at the time of surgery
for catheter implantation (Figures 3 and S2). A very similar
pattern of C-FOS activation (and of denervation effect) took
place in the main hypothalamic regions, where neurons are pro-
jected from the NTS, notably the paraventricular nucleus (PVN),
the lateral hypothalamus (LH) and the arcuate nucleus (ARC)(Figure S2). In the same manner, C-FOS activation occurred in
the periaqueductal gray (PAG), a nucleus receiving inputs from
the PBN, following Nalox infusion, whereas activation did not
take place in this nucleus in capsaicin-denervated rats (Fig-
ure S2). When surgical disruption of the common hepatic branch
of vagus was performed instead of capsaicin denervation,
C-FOS activation induced by Nalox was cancelled in the NTS
and in the downstream PVN but was still present in the PBN
and in the PAG (Figure S3).
Proteolytic Digests and Oligopeptides Exhibit MOR
Antagonist Properties
When rats were previously fed on a PED for 3 days, there was
a marked increase in amounts of G6PC and PEPCK-C proteinCell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc. 379
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Figure 2. Presence of MORs within theWalls of the
Portal Veins in Rats and Humans
(A) MORs (green, left) colocalized with specific neuronal
marker ubiquitin carboxy-terminal hydrolase PGP9.5
(red, middle) in the walls of the portal vein of both rats and
humans. Right: merged images. The arrows point out
the neural fibers innervating the wall of the portal vein. The
arrowheads point out nerve bundles in the vicinity of the
portal vein. Bottom:, MOR was visualized in the Auer-
bach’s plexus (the nervous system innervating the
muscular layers of the intestinal wall, which controls
motility) as a positive control. White bar: 50 mm in portal
veins, 25 mm in the Auerbach’s plexus. The data shown are
representative of portal veins from three rats and portal
branches from four different human samples.
(B) Western blot analysis of the presence of MOR-1 in the
ileum and the portal vein of rats and its absence in the
ileum of MOR-KO mice as a control of specificity.(compare Figure 4 and Figures 1A and 1B). Infusing MOR
agonists in the portal vein of PED-fed rats reversed increases
of G6PC and PEPCK-C protein. On the contrary, no additional
induction effect took place when infusing MOR antagonists
(Figure 4). The same pattern was observed with a PED contain-
ing a mixture of milk caseins (which might possibly release b1-7
or CasoC into the blood) (Figure 4), or with a PED from plant
proteins (i.e., soy, which did not contain these moieties) (Fig-
ure S4). This suggests that MOR antagonists and PED from
any origin could induce intestinal gluconeogenesis gene expres-
sion via the same mechanistic pathway.
To document the above assumption, we combined several
approaches. First, we infused a proteolytic digest (peptones)
and selected oligopeptides (di- or tripeptides) separately into
the mesenteric-portal vein of rats. The following structures
were selected to match the di- or tripeptides with or without
a lateral chain (Tyr-Ala and Gly-Gly, respectively) or with an
electric charge in the lateral chain (Phe-Pro-Arg). In all cases,
a marked induction of G6Pase was observed in both the jejunum
(Figure 5A) and the ileum, a gut portion of weaker G6Pase activity
in the basal state, but inducible in the case of PED feeding
(Mithieux et al., 2005) (Figure 5B). In Figure 5, peptones were
from amixture of caseins. However, peptones frommeat protein
had the same effect (not shown). In addition, glucose tracer dilu-
tion studies revealed that IGP took place after the portal infusion
of Tyr-Ala and peptones separately (Figure 1C). Finally, as
observed previously for MOR antagonists (Figure S1), no induc-
tion of G6Pase by oligopeptides took place in rats with capsaicin
denervation of the periportal area (Figure 5). Second, in rats
infused with Tyr-Ala, there was a 3-fold increase in C-FOS
expression in the DVC (Figures 3B and 3G) and in the hypothal-
amus, the PBN and the PAG (Figure S2), just like the rats infused
with Nalox. Furthermore, no increase in C-FOS took place after380 Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc.inactivation of portal afferents (Figures 3B, 3H,
and S2). Third, we tested whether or not oligo-
peptides could behave as MOR antagonists in
a neuroblastoma cell constitutively expressing
MOR (Lorentz et al., 1988; Yang et al., 2000).
(1) We checked that labeled (tritiated) DAMGObound to N1E-115 cells and that unlabeled DAMGO competed
for binding with a 50% inhibitory concentration (IC50) of about
107M, thus confirming previous results (Zhang et al., 2006).
Then, we showed that Tyr-Ala and Gly-Gly competed for the
binding of tritiated DAMGO with IC50 means of 3.10
6M and
9.107M, respectively. Peptones also competed efficiently with
tritiated DAMGO (data not shown). (2) We studied the effect of
oligopeptides on the coupling of MOR to adenylate cyclase in
the same cells. Concomitant with the fact that MOR is coupled
via G-protein-inhibiting adenylate cyclase, the agonist DAMGO
strongly decreased cell cAMP content (Figure S5). On the
contrary, the antagonists CasoC and Nalox dramatically
increased cell cAMP content. This is in keeping with a previous
observation: an endogenous activity of MOR may exist,
constantly depressing the cAMP level even in the absence of
an agonist. This endogenous activity may be eliminated on
antagonist binding, thus promoting an increase of cAMP (Kotz
et al., 2000). It is noteworthy that all oligopeptides increased
the cAMP content and could prevent the decrease of DAMGO-
induced cAMP in coincubation experiments (Figure S5). This
strongly suggests that oligopeptides exhibited MOR antagonist
properties.
MOR-Dependent Induction of Intestinal
Gluconeogenesis Is a Causal Link in the Satiety Effects
of Food Proteins
To demonstrate the causal role of MORs in the protein-digest-
dependent induction of intestinal gluconeogenesis and its
role in associated satiety, we performed experiments of portal
infusion on mice with deletion of Mor (MOR-knockout) and
on mice with intestine-specific deletion of G6Pase (I-G6pc-
knockout, G6PC being the catalytic subunit of G6Pase). There
was a slight basal induction of gluconeogenic enzymes in
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Figure 3. Effect of Portal Infusion of MOR Agonists and Antagonists on C-FOS Expression in the Dorsal Vagal Complex of Rats
(A, C, E and G) C-FOS immunoreactive cells in the DVC of rats infused via the portal vein with saline only (A), b1-7 (C), Nalox (E), and Tyr-Ala (G) (at a rate of
8.3.106 mmol/kg/min).
(B) Quantification of C-FOS neurons in all areas of the DVC: saline (white bar), b1-7 (black bar), Nalox (gray bar). Open bars: sham-treated rats; dashed bars:
capsaicin-treated rats. Data are expressed as means ± SEM (n = 3) of immunoreactive cells per brain hemisphere. The values with different letters differed
significantly (p < 0.05, Kruskal-Wallis nonparametric test, followed by Dunn’s post hoc test).
(D, F, and H) Comparable infusions of b1-7 (D), Nalox (F) and Tyr-Ala (H) in rats previously treated by capsaicin around the portal vein.
Scale bar: 200 mm. The following abbreviations are used: AP, area postrema; NTS, nucleus of the solitary tract; dmnX, dorsal motor nucleus of the vagus. See also
Figures S2 and S3.
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Rats with portal catheters were fed the PED diet for 2 weeks before infusion.
Infusion with MOR effectors was performed as in Figure 1.
(A) G6Pase activity.
(B and C) Quantification of G6PC and PEPCK-C proteins by western blotting.
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See also Figure S4.
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Figure 5. Effect of Oligopeptides and Protein Digests on G6Pase
Enzyme Expression in the Rat Intestine
Rats with portal catheters (fed on SED) were infused for 8 hr with the indicated
metabolites at the indicated rates. The rate of infusion of peptones was
calculated to match the rate of appearance of protein digests derived from the
assimilation of an SED (low dose) or PED (high dose). The shaded bars refer to
experiments in rats treated locally with capsaicin around the portal vein.
(A) Glc6Pase activity in jejunum.
(B) Comparable determinations performed in a distal ileum segment. The data
are the means ± SEM (n = 6). Statistics are as described in the legend of
Figure 1.
See also Figure S5.MOR-KO mice (Figures S6A and S6B). Again, this is in line with
the basal tone of MORs in wild-type (WT) mice (see above),
which would not exist in MOR-KO mice. When infused in WT382 Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc.mice, di- and tripeptides and peptones induced G6Pase activity
in the jejunum (Figure 6A). On the contrary, DAMGO suppressed
G6Pase activity, and this was inversed by peptones in coinfusion
experiments (Figure 6A). It is noteworthy that none of these
effectors induced any effect on gut gluconeogenesis in MOR-
KO mice (Figure 6B). Furthermore, we studied food intake in
MOR-KO and WT mice after a switch from starch-enriched diet
(SED) to PED. Food intake per day for both groups was not
different with SED. After a transient drop, a classic response to
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See also Figure S6.changes in food type in rodents, food intake was reduced by
about 20% in WT mice fed with a PED. On the contrary, MOR-
KO mice resumed their previous food intake (Figure 6C). It is
noteworthy that this insensitivity to PED was linked to an
absence of modulation of intestinal G6Pase. This highlights
a dramatic difference from the induction effect shown in WT
mice (Figure S6C). Lastly, we studied the food intake in WT
and I-G6pc-KO mice infused with an MOR antagonist via the
portal vein. There was a 15% decrease in the amount of food
ingested in WT mice infused with Nalox (Figure 6D), i.e., mice
exhibiting increased intestinal gluconeogenesis (Figure 6A). In
contrast, no effect was observed upon the infusion of Nalox
in I-G6pc-KO mice, i.e., in the absence of intestinal gluconeo-
genesis (Figure 6D). Comparable results were obtained when
Tyr-Ala was infused instead of Nalox (13% decrease in the
amount of food ingested in WT mice, no diminution in I-G6pc-
KO mice). Taken together, these data strongly suggest that
MOR-mediated intestinal gluconeogenesis and MOR-mediated
modulation of hunger are closely linked phenomena, whichmay account for the satiety effect of food protein following their
assimilation.
DISCUSSION
By combining infusions of MOR effectors in the portal vein in
conscious rats and experiments of denervation of the portal
vein walls, we demonstrate that MORs associated with portal
neuronal fibers initiate a gut-brain neural circuit of induction of
intestinal gluconeogenesis, a function controlling food intake
(Mithieux et al., 2005). An infusion into the gut lumenwould better
mimick the in vivo appearance of protein digests. However, the
flux of native peptide metabolites is difficult to monitor from
the gut lumen due to its high protease content. The neural
system immediately surrounding the intestinal mucosa is by-
passed under the experimental conditions of portal infusion.
Therefore, even if infused metabolites are sensed in the portal
area under the experimental conditions studied here, it cannot
be excluded that MOR-dependent sensing may also, underCell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc. 383
physiological conditions, take place upstream in the neural
system surrounding the gut mucosa or in the gut muscular layer
(Hedner and Cassuto, 1987; Sternini, 2001).
Neural afferents traveling along the ventral trunk of the vagus
nerve are likely to be involved in the transmission of the MOR
signal to the brain. In support of this view, the activation of
both the NTS and hypothalamus induced by MOR antagonists
(revealed by C-FOS expression) is suppressed either by capsa-
icin treatment or by surgical vagotomy. However, the signals
conveyed via the spinal cord, i.e., spino-mesencephalic route
(PBN and PAG), are likely to be involved as well. In agreement
with this assumption, both the PBN and the PAG, which connect
afferents from the spinal cord, are activated via portal MOR
antagonists. Moreover, the activation in these nuclei is sup-
pressed via periportal treatment by capsaicin (a treatment that
ablates the afferents of either route) and not by surgical
vagotomy (a treatment that preserves the spinal afferents). Inter-
estingly, the NTS, hypothalamus, and spino-mesencephalic
pathways are all known to be involved in the control of energy
homeostasis (see Berthoud, 2004 for a review).
It is established that proteins are partially digested within the
gut lumen to oligopeptide moieties mainly composed of di- or tri-
peptides (Daniel, 2004). These oligopeptides are then trans-
ported within enterocytes by means of a specific transporter
(PepT1) of the luminal membrane (Boll et al., 1994; Nielsen and
Brodin, 2003). A fraction undergoes further proteolysis to amino
acids to feed the intestinal amino acid pool. Another fraction is
released into the portal blood, together with amino acids, via
specific oligopeptide and amino acid transporters located at
the basolateral membrane (Lee, 2000). A number of proteins
have been shown to release proteolytic digests with m-opioid
activity (see above). However, the assumption that any food
protein could induce intestinal gluconeogenesis via a MOR-
dependent pathway implied that the proteolytic digests or
peptides of any protein origin could exhibit MOR antagonist
activity. This inference is strongly supported by the observation
herein that peptides, either alone or in mixture (peptones),
behave asMOR antagonists both in vivo to induce gut gluconeo-
genesis and in vitro in experiments of coupling to adenylate
cyclase. The absence of these regulations in MOR-KO mice
and their insensitivity to PED feeding, along with the incapacity
of MOR antagonists tomodulate food intake inmice with ablated
intestinal gluconeogenesis, together confirm a causal link
between MOR antagonism by oligopeptides and the satiety
effect induced by food protein.
These findings may appear difficult to reconcile with the liter-
ature reporting that oligopeptides and food protein digests could
behave as either MOR agonists or MOR antagonists (Capasso
et al., 1997; Moritoki et al., 1984; Schiller et al., 2002; Shiomi
et al., 1981, Zioudrou et al., 1979). However, following ligand-
receptor interaction, various MOR-initiated cellular processes
occur, such as receptor internalization, intracellular sorting and
recycling (Bo¨hm et al., 1997; Sternini et al., 2000). This results
in complex adaptations including receptor downregulation,
desensitization, and resensitization, depending on the concen-
tration of the ligand and on the time of exposure. These cumula-
tive phenomena make the resulting downstream effects of
MOR-modulators (i.e., agonist-like or antagonist-like) almost384 Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc.unpredictable (for a review see Taylor and Fleming, 2001). Alto-
gether, this probably accounts for some of the inconsistent
results published in the field and may also explain, at least
partially, why the different metabolites studied herein did not
always elicit clear dose-dependent effects (see e.g., Figure 1
or Figure 5). In addition, the Mor gene family is highly complex
and includes multiple splice variants and various promoters, de-
pending on its expression site (Pan, 2005). These splice variants
may be functionally distinct, regarding their regulation by various
agonists or antagonists, or depending on their location (Pan,
2005; Pasternak et al., 2004). Therefore it is possible that the
general antagonist behavior of peptides and protein hydroly-
sates revealed here is a specific feature of MORs expressed in
the mesenteric-portal system.
Another intriguing question relates to the complexity of the
sequence of events, which allows the alimentary protein to exert
their satiety end-point action. Indeed, a number of known
factors, e.g., intestinal hormones, arise from the gut driven by
the meal and are assumed to affect food intake by binding their
receptors directly in the hypothalamus. These are rapidly acting
mechanisms. In the case of food proteins, a series of events initi-
ates the gluconeogenesis gene program in the intestine, via
a reflex arc with the brain. This is progressive and takes place
over the postprandial period (Figure 7). After that, the glucose
released may initiate its central action via portal-sensing driven
mechanisms (Mithieux et al., 2005). This is a lasting phenomenon
because it depends on gene induction and thusmay endure after
food assimilation. This is in line with the fact that protein feeding
decreases hunger some time from the preceding meal, which is
the definition of the phenomenon called ‘‘satiety’’ (Booth et al.,
1970; Rolls et al., 1988). This might explain why protein feeding
decreases food intake in the long term, i.e., for several days or
weeks (Jean et al., 2001; Mithieux et al., 2005; Penhoat et al.,
2011). Hence, advantages exist in terms of reduction of body
weight and adipose tissue mass (Jean et al., 2001, Mithieux
et al., 2005). On the contrary, rodents treated before meals
with the satiation hormone CCK, which is involved in the meal
termination, do not reduce their global food intake. Indeed,
they compensate the CCK-initiated decrease of meal size by
increasing the number of meals per day (West et al., 1984). To
evaluate the long-term potential effect of MOR modulators,
lasting portal infusion experiments would have been of interest.
It is likely that benefits on the adipose tissue mass and body
weight would be similar to those observed with protein feeding.
Unfortunately, technical problems (portal catheters blocked or
pulled out) are very frequent after a few days, making such
experiments infeasible.
In conclusion, we report that MORs expressed in the mesen-
teric-portal area control a gut-brain neural circuit of regulation
of intestinal gluconeogenesis. The latter controls food intake
(Mithieux et al., 2005; Penhoat et al., 2011, Troy et al., 2008).
The regulatory role of MORs in the control of food intake has
been largely documented for the central nervous system, related
to their roles in the so-called ‘‘reward’’ system (Glass et al., 1999;
Shin et al., 2010). Here, we report that MORs play a role in medi-
ating the satiety effects of alimentary proteins, acting within
a neural gut-brain circuit (Figure 7). Remarkably, various m-opioid
antagonists given orally decrease hunger in humans (Yeomans
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(B) During the postabsorptive period, glucose released in the portal blood is sensed by the portal glucose sensors and exerts its satiety effects (Mithieux et al.,
2005).and Gray, 2002), despite the fact that they do not reach the brain
due to extensive first-pass hepatic metabolism (Reimer et al.,
2009). Gastric bypass, an increasingly popular surgical opera-
tion treating morbid obesity, promotes a dramatic reduction
of hunger sensation in a few days. This is true in obese mice
(Troy et al., 2008) and in obese humans (for a review see Thaler
and Cummings, 2009). Although intestinal gluconeogenesis was
revealed to be involved in the decreased food intake after gastric
bypass in mice (Troy et al., 2008), a net portal release of glucose
under postabsorptive conditions has been observed several
days after gastric bypass in nondiabetic obese patients (Hayes
et al., 2011). This suggests that intestinal gluconeogenesis could
be sufficient to compensate and even surpass gut glucose utili-
zation. As MOR-positive neural fibers are present in the wall of
the human portal vein branches (Figure 2A), the mechanisms
uncovered here may also take place in humans. This knowledge
may thus pave the way for future approaches in the treatment
and/or prevention of metabolic diseases.
EXPERIMENTAL PROCEDURES
Animals and Tissue Sampling
Adult male Sprague-Dawley rats (Charles River), aged 6 to 8weeks and weigh-
ing 260–280 g at the time of their arrival, were housed in a climate-controlled
room (22 ± 2C) subjected to a 12 hr light/dark cycle with lights on at
7:00 AM and lights off at 7:00 PM, with free access to water and an SEDdiet. Mice were housed under similar conditions. A colony of MOR-KO mice
(Jackson Laboratories) was generated in our facilities from two couples of
mice. I-G6pc-KO mice were described previously (Penhoat et al., 2011). The
experiments were performed 5 weeks after gene deletion. PED composition
was based on SED (SAFE A04, France), with a modification of starch-glucose:
protein ratio from 50:23 to 23:50 (weight basis). Proteins were an equimolar
ratio of soy proteins and casein. However, soy proteins were used for only
a few experiments. The intestine was sampled as described previously
(Mithieux et al., 2004a). Enzyme expression analyses were performed in prox-
imal jejunum in all but a few experiments (Figure 5B). Glc6Pase activity was
assayed under conditions of maximal velocity. All procedures were described
in detail previously (Mithieux et al., 2004a; Rajas et al., 1999).
Studies in Conscious Animals
Animals were anesthetizedwith 2% isoflurane. A catheter was implanted in the
inferior left mesenteric vein after laparotomy and secured with biological glue.
A passage under the skin up to the neck was done to recover the other end of
the catheter, which was secured with a Dacron mesh button tether (Harvard
apparatus). The procedure to implant a portal catheter (PE10, Fine-Bore
Polyethylene Tubing, SmithsMedical) inWT and I-G6pc-KOmice was compa-
rable. In rats intended for portal vein denervation, a gauze compress moist-
ened with 80 ml of a capsaicin solution (10 mg/ml) dissolved in water, ethanol,
and Tween at a ratio of 8:1:1 was applied around the portal vein for 15 min.
Regarding vagotomy studies, the left and caudal lobes of the liver were gently
deflected, and the hepatic branch of the vagus, along with the fascia
surrounding the nerve, was sectioned with fine scissors. Animals were allowed
to recover from the surgery for 1 week, with free access to SED and water.
A marbocyl/ketofen solution was infused each day, in order to prevent
coagulation, infection, and pain.Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc. 385
Portal infusions (at a rate of 125 ml/hr for rats and 15 ml/hr for mice) were
carried out for 8 hr, starting at 9 A.M., in animals with free access to food
and water. Saline was infused as a control vehicle. The following metabolites
were infused: [D-Ala2, N3-Me-Phe4, Gly5-ol]-enkephalin (DAMGO), human
b1-7, Nalox, peptones from meat protein (Sigma-Aldrich), CasoC (kindly
provided by Damien Ficheux, IBCP, Lyon, France), dipeptides H-Tyr-Ala-OH
and H-Gly-Gly-OH, and tri-peptide H-Phe-Pro-Arg-OH (Bachem). Following
the infusions, the animals were anesthetized with sodium pentobarbital for
tissue sampling.
To study food intake in WT and MOR-KO mice (Figure 6C), basal consump-
tion was determined for 5 days before switching to PED. Then, we measured
food intake every day for 15 days. To study the effect of Tyr-Ala in WT and
I-G6pc-KO mice (Figure 6E), portal infusions were carried out for 24 hr and
the amount of food ingested quantified at the end. Each mouse was studied
alternatively for saline or Nalox infusion, including 1 day without experiment
between infusions.
Determination of Intestinal Glucose Fluxes
After an 8 hr infusion of metabolites, as described above (but with no food for
the last 6 hr), rats were anesthetized and fitted with polyethylene catheters
inserted into the right jugular vein for 3[3H]glucose infusion and into the left
carotid artery for blood sampling, as described previously (Croset et al.,
2001; Mithieux et al., 2005; Rajas et al., 1999). At the end of the additional infu-
sion time (for 90min), blood was sampled from the carotid artery and the portal
vein. Blood plasma was separated and deproteinized and used to determine
glucose concentration and specific activity (SA). All calculations were done
by using the formulas described in detail by Croset et al. (2001).
Microscopy Studies
Animals were deeply anesthetized with intraperitoneal injection of sodium
pentobarbital, and transcardially perfused with 0.9% NaCl followed by ice-
cold phosphate-buffered (pH 7.4) paraformaldehyde (PFA). Tissues were
postfixed in PFA for 2–3 hr and cryoprotected in 30% sucrose in phosphate-
buffered saline (PBS) with thimerozal (0.01% v/v). Before freezing, the samples
were embedded in Tissue-Tek (Sakuro Finetek), and vessels and portions of
the intestine were injected with the same substance. Human portal branches
were sampled from healthy portions of hepatectomized livers and immediately
postfixed by immersion in PFA as described above. Serial 20 mm thick sections
were cut on a freezing cryostat.
Immunofluorescence
Sections were preincubated in PBS with 0.3% Triton X-100 (PBST) containing
5% bovine serum albumin (blocking solution) for 2 hr and further incubated
with the primary antibody in the blocking solution overnight at room tempera-
ture. After several rinses in PBST, sections were incubated in the secondary
antibody for 2 hr at room temperature. For double labeling, the protocol
was repeated with the other antibodies after three 15 min washes in PBST.
Staining was absent in the control experiment with omission of primary anti-
bodies. Furthermore, we checked that no cross-reactivity between antibodies
occurred, as assessed by inverting the order of staining and omitting the
second primary antibody (data not shown). Images were generated by using
a fluorescence microscope (Carl Zeiss Axiovert 200M).
See also Table S1.
C-FOS Labeling
Prior to any incubation, endogenous tissue peroxidase activities were
quenched with 1% H2O2 in PBS for 30 min. The procedure was then the
same as described before for primary and secondary antibody incubations.
Following PBS washes, the ABC Elite reagent (Vector Laboratories) was
applied for 45 min. The sections were then incubated in 3,30-diaminobenzidine
(DAB), in conjunction with 5 mg/ml nickel and ammonium sulfate (Sigma-
Aldrich) for 15 to 30 min at a concentration of 0.5 mg/ml in PBS with 0.03%
H2O2. Sections were thoroughly washed, air-dried, dehydrated, and coverslip-
ped. For the quantitative assessment of C-FOS expression in the brain, four
to six sections were chosen in areas in the hypothalamus, PBN, and PAG,
as well as in the brain stem, according to Paxinos and Watson (1998). Images
were generated with a light microscope (Nikon Eclipse E400) and FOS-positive386 Cell 150, 377–388, July 20, 2012 ª2012 Elsevier Inc.nuclei were counted by using a calibrated macro as described before (Zheng
et al., 2002) with ImageJ software (U. S. National Institutes of Health, Be-
thesda, Maryland, USA, http://imagej.nih.gov/ij/). All data are expressed as
FOS-positive neurons per hemisphere of the brain.
See also Table S1.
Statistical Analyses
Data are expressed as means ± SEM. One-way ANOVA followed by Tukey’s
post hoc test was used for multiple parametric comparisons. Student’s two-
tailed paired t test was used for paired comparisons. The nonparametric
Kruskal-Wallis test followed by Dunn’s post hoc test was used for C-FOS posi-
tive neuron counting. Statistical significance was set at p% 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.05.039.
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